Pharmacokinetic properties of insulin GZR4 after subcutaneous administration in the thigh, abdomen, or upper arm in healthy participants

Documenti analoghi

• Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trial
  di: Chengyong Tang, et al.
  Pubblicazione: (2025)
• The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects
  di: Yue Liu, et al.
  Pubblicazione: (2025)
• Pharmacokinetics and pharmacodynamics of oral insulin ( ORMD ‐0801) in healthy subjects: A phase I study using hyperinsulinaemic‐euglycaemic clamp
  di: Yufei Chen, et al.
  Pubblicazione: (2025)
• Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta‐analysis of randomised controlled trials
  di: Kitti Thammakosol, et al.
  Pubblicazione: (2025)
• Correction to ‘Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta‐analysis of randomised controlled trials’
  Pubblicazione: (2026)